Cite
Buchler T, Chloupkova R, Poprach A, et al. Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer Manag Res. 2018;11:359-368doi: 10.2147/CMAR.S183093.
Buchler, T., Chloupkova, R., Poprach, A., Fiala, O., Kiss, I., Kopeckova, K., Dusek, L., Veskrnova, V., Slavicek, L., Kohoutek, M., Finek, J., Svoboda, M., Petruzelka, L., & Melichar, B. (2019). Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer management and research, 11359-368. https://doi.org/10.2147/CMAR.S183093
Buchler, Tomas, et al. "Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis." Cancer management and research vol. 11 (2019): 359-368. doi: https://doi.org/10.2147/CMAR.S183093
Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B. Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. Cancer Manag Res. 2018 Dec 28;11:359-368. doi: 10.2147/CMAR.S183093. eCollection 2019. PMID: 30643461; PMCID: PMC6314050.
Copy
Download .nbib